Ashok Dhanrajgir
Senior Vice President @ Inventages Venture Capital Investment Inc.
Ashok Dhanrajgir is a Series B investor at Inventages Venture Capital Investment Inc. focused on Medical and Health Care. Ashok brings more than 20 years of international healthcare experience, focused primarily on Corporate & Business Development, Mergers & Acquisitions and Strategic Planning within leading multinational corporations where he was responsible for a number of transformational deals and exits. His breadth of experience includes the uniqueopportunity of being involved in positions of significant influence across the sectors of functional foods, consumer health, pharmaceuticals and biotech. Additionally, he has built a powerful and considerable network that enables global access to healthcare corporations, financial and high net worth communities.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Ashok Dhanrajgir invests in
Stages Ashok Dhanrajgir invests in
Countries Ashok Dhanrajgir invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Phagenesis
|
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $17M / Series B / May 22, 2013 | |
|
Phagenesis
|
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $7.7M / Series B / Oct 04, 2011 |
Inventages Venture Capital Investment Inc is an investment arm of Nestle SA specializing in PIPES, seed, early, mid, and late venture investments. The firm seeks to invest in middle market and mature companies. It provides mezzanine and bridge financing. The firm seeks to invest in health care, life sciences, cosmeceuticals, pharmaceuticals,enabling technologies and services, and diagnostic and medical devices. Within the pharmaceutical sector, it typically invests in small molecules, proteins, antibodies, vaccines, phytopharmaceuticals, natural compounds, botanicals, antibiotics, and therapeutics. Within the diagnostic sector, it focuses on genetic materials, biomarkers, pathological markers, genetic profiles, protein profiles, pharmacogenomics, food and environmental safety, genetically modified organism detection and trading, medical monitoring, diagnostic and analytical tools, and quality control. Within enabling technologies and services it primarily invests in novel packaging, process and production technologies, supply chain management, innovative materials and resources, delivery systems for active compounds, encapsulation and prevention, food services, extraction and fractionation of biological materials, consumer relation management, green biotechnology, smell and taste modifying technologies, genomics, proteomics, metabolomics, screen and characterization technologies, chemical and biological engineering, and innovative preventive and therapeutic concepts. It also invests in companies involved in the prevention of medical foods, nutraceuticals, cosmoceuticals, nutrition, innovative food, functional food, dietary and food supplements, oral and skin care, immune modulation and stimulation, and health and disease management.
Inventages Venture Capital Investment Inc. Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ashok Dhanrajgir
Senior Vice President
|
|||
Hervé Girsault
Venture Partner
|
|||
Bill Kermode
Partner
|
|||
Erich Sieber
Senior Vice President
|
|||
François Struye de Swielande
Senior Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ashok Dhanrajgir invest in?
Ashok Dhanrajgir invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ashok Dhanrajgir?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ashok Dhanrajgir last invest?
The most recent investment recorded for Ashok Dhanrajgir closed in May 2013. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
